KDM4 INHIBITORS

WIPO Patent Application WO/2018/183370

A3

The present disclosure relates generally to compounds and methods for inhibiting the enzymatic activity of lysine demethylase 4 (KDM4) and treating cancer. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibiting lysine demethylase 4. Furthermore, the subject compounds and compositions are useful for the treatment of breast cancer and the like.

WO1999061040	USE OF alpha 1 beta 1 INTEGRIN RECEPTOR INHIBITORS AND TGF- beta 1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
JP6736540	Treatment of cancer with CLL-1 chimeric antigen receptor
WO/2007/106884	METHODS OF TREATING MUSCULAR WASTING DISEASES USING NF-KB ACTIVATION INHIBITORS

SCHULE ROLAND (DE)
METZGER ERIC (DE)

PCT/US2018/024624

December 20, 2018

March 27, 2018

Click for automatic bibliography generation  

UNIV FREIBURG ALBERT LUDWIGS (DE)
CELGENE QUANTICEL RES INC (US)

A61K31/436; A61K31/4412; A61K31/444; A61K31/5377

US9242968B2	2016-01-26
US20150267241A1	2015-09-24
US20150291529A1	2015-10-15

GARCIA ET AL.: "KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer", BREAST CANCER: BASIC AND CLINICAL RESEARCH, vol. 10, November 2016 (2016-11-01), pages 169 - 175, XP055560818
CHEN Y.K., ET AL.: "Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 8, 27 July 2017 (2017-07-27), pages 869 - 874, XP055560820
METZGER ET AL.: "KDM4 inhibition targets breast cancer stem-like cells", CANCER RESEARCH, vol. 77, no. 21, 7 September 2017 (2017-09-07), pages 5900 - 5912, XP055560824

SUNG, Lawrence M. et al. (US)

View/Download PDF      PDF Help

Previous Patent: CRANBERRY-DERIVED COMPOSITIONS FOR POTENTIATING ANTIBIOTIC EFFICACY AGAINST BACTERIAL PERSISTENCE

Next Patent: COOLING TOWER WITH DIRECT AND INDIRECT HEAT EXCHANGER